Effects of tamoxifen on cardiovascular risk factors in postmenopausal women

Annals of Internal Medicine

Volumn 115, Issue 11, 1991, Pages 860-864

  Love, Richard R ^a,b   Wiebe, Donald A ^a,c   Newcomb, Polly A ^a,d   Cameron, Linda ^a,b   Leventhal, Howard ^a,e   Jordan, V Craig ^a,c   Feyzi, Jan ^a,d   DeMets, David L ^a,d  

^a UNIVERSITY OF WISCONSIN   (United States)

^b University Hospitals and Clinics ^*  (United States)

^c University of Wisconsin Health   (United States)

^d Medical Science   (United States)

^e RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; FOLLITROPIN; GEMFIBROZIL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROBUCOL; TAMOXIFEN; TRIACYLGLYCEROL;

ADULT; BLOOD PRESSURE; BREAST CANCER; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; CARDIOVASCULAR DISEASES; CHOLESTEROL; DOUBLE-BLIND METHOD; FEMALE; HUMAN; LIPIDS; LIPOPROTEINS; MENOPAUSE; MIDDLE AGE; RISK FACTORS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TAMOXIFEN;

EID: 0025931791     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-115-11-860     Document Type: Article

References (26)

1. Lerner LJ, Jordan VC. Development of antiestrogens and their use in breast cancer: eighth Cain memorial award lecture. Cancer Res. 1990;50:4177-89.
2. Love RR. Tamoxifen therapy in primary breast cancer: biology, efficacy, and side effects. J Clin Oncol. 1989;7:803-15.
3. Early Breast Cancer Triabts' Collaborative Group. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,8% women N Engl J Med. 1988;319:1681-92.
4. Fisher B, Brown A, Wolmark N, Redmond C, Wickerham DL, Wittliff J, et al. Prolonging tamoxifen therapy for primary breast cancer. Findings from the National Surgical Adjuvant Breast and Bowel Project clinical trial. Ann Intern Med. 1987;106:649-54.
5. Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC). Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial. Lancet. 1987;2:171-5.
6. Falkson HC, Gray R, Wolberg WH, Gillchrist KW, Harris JE, Tormey DC, et al. Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal women with breast cancer: an Eastern Cooperative Oncology Group phase III study. J Clin Oncol. 1990; 8:599-607.
7. Boccardo F, Rubagotti A, Bruzzi P, Capoellini M, Isola G, Nenci I, et al. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: results of a multicentric Italian study. J Clin Oncol. 1990; 8:1310-20.
8. Jordan VC. Chemosuppression of breast cancer with tamoxifen: laboratory evidence and future clinical investigations. Cancer Invest. 1988;6:589-95.
9. Love RR. Prospects for antiestrogen chemoprevention of breast cancer. J Natl Cancer Inst. 1990;82:18-21.
10. Love RR, Newcomb PA, Wiebe DA, Surawicz TS, Jordan VC, Carbone PP, et al. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst. 1990;82:1327-32.
11. Love RR, Canteron L, Connell B, Leventhal H. Symptoms associated with tamoxifen treatment in post-menopausal women. Arch Intern Med 1991;151:1842-7.
12. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
13. Rifai N, King ME. Immunoturbidimetric assays of apolipoproteins A, A-I, A-II, and B in serum. Clin Chem. 1986;32:957-61.
14. Curme HG, Columbus RL, Dappen GM, Eder TW, Fellows WD, Figueras J, et al. Multilayer film elements for clinical analysis: general concepts. Clin Chem. 1978;24:1335-42.
15. Wei LJ, Lachin JM. Two-sample asymptomically distribution-free test for incomplete multivariate observations. Journal of the American Statistical Association. 1984;79:653-61.
16. Powles TJ, Hardy JR, Ashley SE, Farrington GM, Cosgrove D, Davey JB, et al. A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br J Cancer. 1989;60:126-31.
17. Bruning PF, Bonfrer JM, Hart AA, de Jong-Bakker M, Linders D, van Loon J, et al. Tamoxifen, serum lipoproteins and cardiovascular risk. Br J Cancer. 1988;58:497-9.
18. Bertelli G, Pronzato P, Amoroso D, Cusimano MP, Conte PF, Montagna G, et al. Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels. Breast Cancer Res Treat. 1988;12:307-10.
19. Sedlacek S. Estrogenic properties of tamoxifen on serum lipids in postmenopausal women with breast cancer [Abstract]. Breast Cancer Res Treat. 1989;14:153.
20. Bagdade JD, Weiter J, Subbaiah PV, Ryan W. Effects of tamoxifen treatment on plasma lipids and lipoprotein lipid composition. J Clin Endocrinol Metab. 1990;70:1132-5.
21. Schapira D, Kumar M, Lyiran GH. The effect of tamoxifen therapy on serum cholesterol [Abstract]. Proceedings of the American Society for Clinical Oncology. 1990;9:49.
22. Skipski VP, Barclay M, Barclay RK, Fetzer VA, Good JJ, Archibald FM. Lipid composition of human serum lipoproteins. Biochem J. 1967;104:340-52.
23. Bush TL, Barrett-Connor E, Cowan LD, Criqui MH, Wallace RB, Suchindran CM, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation. 1987;75:1102-9.
24. Love RR, Surawicz TS, Williams EC. Antithrombin III, fibrinogen, and platelet number changes with adjuvant tamoxifen therapy. Arch Intern Med. 1991 [In press]
25. Stewart H. Consensus Conference on Adjuvant therapy in node negative breast cancer. Washington, DC, 18 June 1990.
26. Manolio TA, Pearson TA, Wenger NK, Barrett-Connor E, Payne GH, Harlan WR. Cholesterol and heart disease in older persons and women: overview of an NHLBI workshop. Am J Epidemiol. 1991; [In press].